Compounds and combinations thereof for treating neurological and psychiatric conditions
This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.
1 . A method of treating agitation associated with Alzheimer's disease in a human patient using an N-methyl D-aspartate (NMDA) receptor antagonist, comprising administering a combination of the NMDA receptor antagonist and a second agent that increases the plasma levels of the NMDA receptor antagonist to the human patient, wherein the NMDA receptor antagonist is dextromethorphan in the free base form at a dose of about 33 mg twice daily, or a molar equivalent amount of a salt form of dextromethorphan, and the second agent is bupropion in the free base form at a dose of 91 mg twice daily, or a molar equivalent amount of a salt form of bupropion, wherein the human patient experiences a reduction in agitation symptoms after one week of treatment that is greater than what would be achieved with a placebo, wherein the human patient has a history of drug abuse, wherein the human patient does not experience depersonalization or derealization disorder, wherein the human patient is monitored for any indication of clinical worsening, and wherein the dextromethorphan and the bupropion are the only therapeutic agents in the combination.
2 . The method of claim 1 , wherein the combination is administered for at least 14 consecutive days.
3 . The method of claim 1 , wherein the combination is administered for at least 30 consecutive days.
4 . The method of claim 1 , wherein the dextromethorphan is in an immediate-release formulation.
5 . The method of claim 1 , wherein the bupropion is in an extended-release formulation.
6 . The method of claim 1 , wherein the combination is administered orally.
7 . The method of claim 1 , wherein the bupropion is in an oral dosage form.
8 . The method of claim 1 , wherein the dextromethorphan is in an oral dosage form.
9 . The method of claim 1 , wherein administering the combination is more effective in treating agitation associated with Alzheimer's disease in the human patient than administering the same amount of the dextromethorphan alone.
10 . The method of claim 1 , wherein administering the combination is more effective in treating agitation associated with Alzheimer's disease in the human patient than administering the same amount of the bupropion alone.
11 . The method of claim 1 , wherein steady state plasma concentrations of dextromethorphan and bupropion are achieved within 8 days.
12 . The method of claim 11 , wherein the accumulation ratio for dextromethorphan at steady state is about 20 based on C max of dextromethorphan.
13 . The method of claim 11 , wherein the accumulation ratio for dextromethorphan at steady state is about 32 based on AUC 0-12 of dextromethorphan.
14 . The method of claim 11 , wherein the accumulation ratio for bupropion at steady state is 1.1 based on C max of bupropion.
15 . The method of claim 11 , wherein the accumulation ratio for bupropion at steady state is 1.5 based on AUC 0-12 of bupropion.
16 . The method of claim 1 , wherein the median T max of dextromethorphan is about 3 hours after administration of the combination.
17 . The method of claim 1 , wherein the median T max of bupropion is about 2 hours after administration of the combination.
18 . The method of claim 1 , wherein the combination is in an oral dosage form when administered.
19 . The method of claim 18 , wherein the oral dosage form is a tablet.
20 . The method of claim 19 , wherein the tablet is a bilayer tablet.
21 . The method of claim 19 , wherein the tablet contains L-cysteine hydrochloride monohydrate, carbomer homopolymer, microcrystalline cellulose, colloidal silicon dioxide, crospovidone, stearic acid, magnesium stearate, or a combination thereof.
22 . The method of claim 19 , wherein administering the combination is more effective in treating agitation associated with Alzheimer's disease in the human patient than administering the same amount of the dextromethorphan alone.
23 . The method of claim 19 , wherein administering the combination is more effective in treating agitation associated with Alzheimer's disease in the human patient than administering the same amount of the bupropion alone.
24 . The method of claim 1 , wherein human patient is at risk of QT prolongation.